FABP4 and hepatocellular carcinoma: These data, together with our functional observation showing attenuation of the effects of ADCM on liver CSC properties in HCC upon treatment with the FABP4-specific inhibitor BMS-309403 (Supplemental Figure 2, A–D), further suggested the critical role of adipocyte-derived FABP4 in the promotion of cancer stemness.